The $178M cash infusion and planned $230M buyback signal strong capital return potential. Monitor for the Genevant parent dividend in Q3 2026, which is a prerequisite for the buyback. The Pfizer/BioNTech lawsuits add significant upside optionality but are early-stage. Traders should watch for any updates on the contingent Moderna payment (up to $1.3B) tied to the 1498 appeal.
ABUS drugs
ABUS drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 16 $4.74entry
- T+1 · 4mo ago −3.80%α −2.81% · $4.56
- T+5 · 4mo ago −5.70%α −4.03% · $4.47
- T+20 · 3mo ago −3.38%α −6.99% · $4.58
- T+60 · 6w ago −10.97%α −14.68% · $4.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arbutus received ~$178M from the Moderna settlement, filed three international patent lawsuits against Pfizer/BioNTech, and announced a plan to return up to ~$230M to shareholders via share repurchases in Q3 2026. The termination of the RSV agreement with Genevant is a minor procedural item with a $1M fee. The combination of a large cash infusion, ongoing litigation upside, and a substantial buyback plan is a clear positive catalyst.
Key Facts
- Received approximately $178M as Arbutus' share of the $950M noncontingent Moderna settlement payment on July 8, 2026.
- Filed three international patent infringement lawsuits (Canada, UPC) against Pfizer/BioNTech seeking injunctions and monetary damages.
- Announced intent to return up to approximately $230M to shareholders via share repurchases, potentially including a modified Dutch Auction tender offer, expected to commence in Q3 2026 after receipt of a dividend from Genevant parent.
- Terminated the RSV agreement with Genevant in exchange for a $1.0M termination fee.
- CEO Lindsay Androski and CFO Tuan Nguyen received litigation-related cash bonuses tied to settlement proceeds (1.5% and 0.25% respectively).
Financial Impact
Arbutus received ~$178M in cash from the Moderna settlement, with potential for up to an additional $1.3B contingent payment and further proceeds from Pfizer/BioNTech litigation. The planned share repurchase of up to ~$230M represents ~25% of current market cap.
Risk Factors
- Contingent Moderna payment of up to $1.3B is subject to uncertain appeal outcomes and may never materialize.
- Pfizer/BioNTech litigation is at an early stage; no guarantee of success or timeline.
- Share repurchase plan is subject to board approval and receipt of dividend; may not occur as described.
- Company is clinical-stage with no approved products; core business risk remains.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-004708 |
| Exhibit: exh_101.htm | 0001171843-26-004708 |
| Exhibit: exh_991.htm | 0001171843-26-004708 |
| Document: 0001171843-26-004708-index-headers.html | 0001171843-26-004708 |
| Document: 0001171843-26-004708-index.html | 0001171843-26-004708 |
| Document: 0001171843-26-004708.txt | 0001171843-26-004708 |
Track record
25 reports on ABUS
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers